+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rheumatoid Arthritis: Update Bulletin #3

  • ID: 4521374
  • Newsletter
  • May 2022
  • Region: Global
  • FirstWord Publishing

Business Questions:

  • How do KOLs perceive Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo?
  • With three adalimumab biosimilars now approved in Europe, what concerns do prescribers have with regard to multiple biosimilar versions becoming available?
  • How do KOLs view Sandoz’s Rixathon, the second rituximab biosimilar to enter the RA space in Europe?
  • Celltrion is currently developing a subcutaneously administered infliximab biosimilar, but what need is there currently for a subcutaneous version of this product?
  • What concerns might prescribers have regarding Celltrion’s subcutaneous infliximab biosimilar?
Note: Product cover images may vary from those shown